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http://www.biomedcentral.com/1471-2407/13/327RESEARCH ARTICLE Open AccessActivation of AMPK inhibits cervical cancer cell
growth through AKT/FOXO3a/FOXM1 signaling
cascade
Mingo Ming Ho Yung1, David Wai Chan1*, Vincent Wing Sun Liu1, Kwok-Ming Yao2
and Hextan Yuen-Sheung Ngan1*Abstract
Background: Although advanced-stage cervical cancer can benefit from current treatments, approximately 30%
patients may fail after definitive treatment eventually. Therefore, exploring alternative molecular therapeutic
approaches is imperatively needed for this disease. We have recently shown that activation of AMP-activated
protein kinase (AMPK), a metabolic sensor, hampers cervical cancer cell growth through blocking the Wnt/β-catenin
signaling activity. Here, we report that activated AMPK (p-AMPK) also inhibits cervical cancer cell growth by
counteracting FOXM1 function.
Methods: Effect of the activation of AMPK on FOXM1 expression was examined by hypoxia and glucose
deprivation, as well as pharmacological AMPK activators such as A23187, AICAR and metformin. RT Q-PCR and
Western blot analysis were employed to investigate the activities of AMPK, FOXM1 and AKT/FOXO3a signaling.
Results: Consistent with our previous findings, the activation of AMPK by either AMPK activators such as AICAR,
A23187, metformin, glucose deprivation or hypoxia significantly inhibited the cervical cancer cell growth. Importantly,
we found that activated AMPK activity was concomitantly associated with the reduction of both the mRNA and
protein levels of FOXM1. Mechanistically, we showed that activated AMPK was able to reduce AKT mediated
phosphorylation of p-FOXO3a (Ser253). Interestingly, activated AMPK could not cause any significant changes in
FOXM1 in cervical cancer cells in which endogenous FOXO3a levels were knocked down using siRNAs, suggesting
that FOXO3a is involved in the suppression of FOXM1.
Conclusion: Taken together, our results suggest the activated AMPK impedes cervical cancer cell growth through
reducing the expression of FOXM1.
Keywords: AMPK, FOXM1, FOXO3a, Cervical cancerBackground
Cervical cancer results from uncontrolled growth of
malignant cells started within the uterine cervix and is one
of the most common malignancies in women worldwide
[1-3]. Although this disease is almost preventable with
routine genetic screening and vaccination, more than 80%
of cervical cancers with a majority in the advanced stage
are currently found in developing countries including
China, leading to a high risk of recurrence and poor* Correspondence: dwchan@hku.hk; hysngan@ hku.hk
1Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The
University of Hong Kong, Hong Kong SAR, People’s Republic of China
Full list of author information is available at the end of the article
© 2013 Yung et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsurvival [2,4]. Thus, there is a compelling need to explore
novel therapeutic interventions for this disease.
Emerging evidence suggests that targeting cancer cell me-
tabolism is a promising therapeutic approach in human
cancers. AMP-activated protein kinase (AMPK) is a known
cellular metabolic sensor and plays an important role in the
control of energy homeostasis in response to external
stresses [5-8]. Recent studies have documented that
pharmacological activation of AMPK is able to block cancer
cell growth in various human cancers [8-11]. Indeed, we
have previously reported that pharmaceutical AMPK
activators such as AICAR (ATP-dependent) and A23187
(ATP-independent) could suppress cervical cancer celltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kinase of AMPK [10]. We also proposed mechanistic
evidence showing that metformin, AICAR and A23187
suppress cervical cancer cell growth through reducing
DVL3, a positive effector of Wnt/β-catenin signaling
cascade which has been shown to be constitutively
active during cervical cancer development [12]. Yet, it
is still believed that there are other molecular mechanisms
by which these pharmaceutical AMPK activators
suppress cancer cell growth. The understanding of
these mechanisms will assist in exploring better therapeutic
regimes when using these drugs.
Forkhead Box M1 (FOXM1) is a member of the
Forkhead Box transcription factors which is essential for
cell proliferation and apoptosis in the development and
function of many organs [13-17]. We previously reported
that aberrant upregulation of FOXM1 is associated with
the progression and development of human cervical
squamous cell carcinoma (SCC) [18]. Biochemical and
functional studies confirmed that FOXM1 is critically
involved in cervical cancer cell growth through upregulating
cyclin B1, cyclin D1 and cdc25B and downregulating
p27 and p21 expressions. These findings suggest that
FOXM1 plays a vital role in cervical cancer cell growth
and oncogenesis.
In this study, we reported that the activated AMPK
inhibits the cell growth by reducing FOXM1 expression
in human cervical cancer cells upon treatments with
hypoxia, glucose deprivation and pharmaceutical AMPK
activators. We provided both biochemical and functional
evidence to support our findings that the repression
of FOXM1 expression of AMPK is dependent on the
AKT/FOXO3a/FOXM1 signaling cascade.
Methods
Cell lines and reagents
Cervical cancer cell lines HeLa, CaSki, C33A and SiHa
(American Type Culture Collection, Rockville, Md.,
USA) (cell line authentication was done by in-house
STR DNA profiling analysis) were employed in this
study. They were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% (v/v) fetal bovine serum (Gibco),
100 units/ml penicillin/streptomycin (Gibco) at 37°C in
an incubator with humidified atmosphere of 5% CO2
and 95% air. AMPK activators AICAR, A23187 and
metformin and AKT inhibitor LY294002 were
obtained from Tocris Bioscience (Bristol, UK). FOXM1
inhibitor Thiostrepton was purchased from Calbiochem
(La Jolla, CA, USA).
Plasmids and cell transfection
To study the effects of enforced FOXM1 expression, the
FOXM1c-expressing plasmid pcDNA3–FOXM1c wasused because the c isoform has higher transactivating ac-
tivity and is expressed dominantly in cells as well as tis-
sues. Whereas, the pcDNA3 empty vector was used in
mock transfections as control. Besides, the vector-based
shRNA plasmid pTER–FOXM1 was used to knockdown
endogenous FOXM1. All of these plasmids had been
described previously [18]. As controls in knockdown
assays, the p-super GFP and pcDNA3 vectors were
used in mock transactions. To knockdown human
FOXO3a, the TriFECTa RNAi Kit which contains
three siRNAs targeting human FOXO3a was purchased
from IDT (Integrated DNA Technologies, Inc., Iowa, USA).
Cell transfection was carried out using LipofectAMINETM
2000 (Invitrogen) according to the manufacturer’s
instructions. Expression patterns were analyzed by
Western blotting. The parental vector pEGFP-C1 was
used as empty vector control.Cell proliferation assay
Cell proliferation kit (XTT) (Roche, Basel, Switzerland)
was used to measure cell viability according to the
manufacturer’s protocol. Three independent experiments
were performed in triplicates.RNA extraction and quantitative reverse transcriptase–
PCR (Q-PCR)
According to the instruction of the manufacturer, total
RNA was extracted using TRIzol reagent (Invitrogen).
Complementary DNA (cDNA) was subsequently synthe-
sized using a reverse transcription reagent kit (Applied
Biosystems, Foster City). The expression level of FOXM1
was then evaluated by q-PCR in an ABI PRISM™ 7500 sys-
tem (Applied Biosystems) using Taqman® Gene expression
Assays; human FOXM1 (Assay ID: Hs00153543_m1). The
human 18S rRNA (Assay ID: Hs99999901_m1) was used as
an internal control.Western blot analysis
Proteins in cell lysates were separated by 10% SDS-PAGE
and transferred to polyvinylidene-difluoride (PVDF) mem-
branes. The membranes were blotted with 5% skimmed
milk and subsequently probed overnight at 4°C with pri-
mary antibodies specific for p-AMPKα, AMPKα, p-AKT,
AKT, p-FOXO3a, FOXO3a (Cell Signaling, Beverly,
MA, USA), FOXM1 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and β-actin (Sigma-Aldrich,
St. Louis, MO, USA) and then incubated with horseradish
peroxidase conjugated goat anti-rabbit or anti-mouse
secondary antibody (Amersham, Uppsala, Sweden).
Immunodetection was performed with enhanced chemi-
luminescent reagent solution (AmershamTM ECLTM)
and visualized using medical X-ray film.
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Student’s t test was applied to the data analysis. All data
were expressed as mean ± SEM. P-value of less than 0.05
was considered as significant.
Results
Increased AMPK activity inhibits cervical cancer cell
growth by suppressing FOXM1 expression
Consistent with our previous findings [12], this study
also showed that the cell growth of cervical cancer cell
lines such as Caski and SiHa was significantly inhibited
by the AMPK activator metformin on a time and dose
dependent manner (Figure 1A). Similarly, other AMPK ac-
tivators such as AICAR and A23187 displayed remarkable
inhibitory effect on cervical cancer cells (data not shown),
confirming that activation of AMPK is able to reduce
cervical cancer cell growth.Figure 1 Activation of AMPK by pharmaceutical AMPK activators sup
showed that the growth rates of cervical cells; Caski and SiHa, were significan
of metformin (10 mM and 20 mM) when compared with the control medium
increased, while the level of FOXM1 was reduced in cervical cancer cells (Cask
metformin (25 mM) for various time points. (C) RT-Q-PCR analysis demonstrat
reduced when treated with metformin (25 mM) and A23187 (2 μM) from 16 hAs FOXM1 is a master regulator of cancer cell
growth, it is of interest to examine whether increased
AMPK activity has any functional impact on FOXM1
in cervical cancer oncogenesis. Upon treatment of
AICAR (1 mM), A23187 (2 μM), metformin (25 mM),
glucose deprivation and hypoxia on the cervical cancer
cell lines Caski, C33A and HeLa, we found that FOXM1
expression was drastically decreased while AMPK activity
[p-AMPK (Thr172)]was elevated concomitantly (Figure 1B
and Figure 2). Interestingly, Q-PCR analysis also demon-
strated that the mRNA level of FOXM1 in C33A and
SiHa cells was remarkably reduced upon treatment of
metformin (25 mM) and A23187 (2 μM) in a time
dependent manner (Figure 1C). This finding indicates
that AMPK activated by these pharmaceutical activa-
tors could suppress FOXM1 expression at both protein
and mRNA levels.presses expression of FOXM1. (A) XTT cell proliferation assay
tly reduced in a dose and time dependent manner upon the treatment
. (B) Western blot analysis showed that the level of p-AMPKα was
i, C33A and Hela) when treated with AICAR (1 mM), A23187 (2 μM) and
ed that the FOXM1 mRNA level of C33A and SiHa cells was remarkably
rs to 24 hrs. The 18S gene was used as an internal control.
Figure 2 Activation of AMPK by glucose deprivation and
hypoxia inhibits cell growth in cervical cancer cells. Caski cells
treated by glucose deprivation and hypoxia at various time intervals
showed an increased of p-AMPKα but a reduction of FOXM1.
Figure 3 Activation of AMPK represses FOXM1 expression
through inhibiting the AKT/FOXO3a signaling pathway. (A)
Upon treatment of metformin (25 mM) in cervical cancer cells
(C33A), the expression of FOXM1 diminished remarkably and the
phosphorylation of AKT and AKT-specific phosphorylation of
FOXO3a (Ser253) decreased concomitantly. (B) Co-treatment of
PI3K/AKT inhibitor, LY294002 (10 μM), inhibited p-AKT and
concomitantly reduced the levels of FOXO3a (Ser253) and FOXM1
in C33A cells. (C) Depletion of endogenous FOXO3a in C33A cells
using siRNAs showed that FOXO3a expression is required for the
suppression of FOXM1 by metformin (25 mM) treatment.
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blocking the AKT/FOXO3a signaling pathway
FOXO3a is well known to be one of the FOXO
transcription factors that functions downstream of
PI3K-PTEN-AKT (PKB) signaling in modulating cell
growth [19]. Along the signaling cascade, FOXO3a is
a negative regulator of FOXM1 expression [20]. To
investigate whether the suppressive effect of AMPK
on FOXM1 is mediated via FOXO3a, we first examined
the intensity of FOXO3a dephosphorylation by metformin.
Upon treatment of metformin (25 mM) on the cervical
cancer cell line C33A, not only FOXM1 expression dimin-
ished remarkably but also the phosphorylation of AKT and
the AKT-specific phosphorylation of FOXO3a (Ser253)
(Figure 3A). We then examined whether the PI3K/AKT
inhibitor LY294002 could reduce FOXM1 expression in
cervical cancer cells. As expected, C33A cells exhibited
decreased intensity of AKT-specific phosphorylation of
FOXO3a (Ser253) as well as FOXM1 expression upon the
treatment of LY294002 (10 μM) (Figure 3B). To further
assess whether FOXO3a is primarily involved in the reduc-
tion of FOXM1 induced by AMPK activation but not an
off-target pharmaceutical effect, siRNA-based knockdown
of FOXO3a in C33A cells was carried out. Western blot
analysis revealed that cervical cancer cells with depletion of
endogenous FOXO3a did not show altered FOXM1expression even when AMPK was activated subsequently
by metformin (25 mM) (Figure 3C). Taken together,
our data support that inhibition of FOXM1 by AMPK
activation is attributed to the repression on AKT and its
downstream, AKT-specific phosphorylation of FOXO3a
(Ser253) in cervical cancer cells.
Ectopic expression of FOXM1 rescues AMPK-mediated cell
growth inhibition
Given that activation of AMPK leads to growth inhibition
of cervical cancer cells through reduction of both the
mRNA and protein levels of FOXM1, we sought to deter-
mine whether enforced expression of exogenous FOXM1
could counteract the AMPK-induced suppressive effect.
C33A and SiHa cells were transiently transfected with
FOXM1c-expressing plasmid and treated with metformin
(20 mM). Consistent with our previous findings [18], XTT
cell proliferation analysis showed that enforced expression
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both C33A (P = 0.00007) and SiHa (P = 0.0004) cells as
compared with the vector control (Figure 4A). Importantly,
C33A and SiHa cells with ectopic expression of FOXM1c
could significantly reduce the effect of AMPK-mediated cell
proliferation inhibition as compared with their vector con-
trols upon treatment of metformin (20 mM) (Figure 4A).
Such counteracting effect of ectopic FOXM1c was
particularly evident in SiHa cells (Figure 4A). Indeed,
Western blot analysis confirmed that there was no reduc-
tion in the expression of FOXM1 in FOXM1c-transfected
SiHa cells upon treatment of metformin (25 mM) for
24 hrs (Figure 4B). Collectively, these findings confirm that
activation of AMPK by hypoxia and glucose deprivation, as
well as pharmacological AMPK activators inhibits cervical
cancer cell growth, and this effect is dependent on
the endogenous expression level of FOXM1.Figure 4 Ectopic expression of FOXM1c could rescue AMPK mediated
proliferation assay showed that the growth rates of C33A and SiHa cells wi
compared with empty vector control (VC). C33A and SiHa cells with ectopi
rate as compared with the vector controls upon treatment of metformin (2
(including exogenous FOXM1c) could not be reduced in SiHa cells when tr
remained constant when C33A cells were treated with FOXM1 specific inh
shRNA knockdown approach could not affect the level of p-AMPKα. Both s
while C1 and C2 represent the vector controls.FOXM1 acts as an AMPK downstream effector
Previous experiments have demonstrated that reduction
of FOXM1 is a common scenario when AMPK is
activated in cervical cancer cells. As FOXM1 is a key
transcription factor, we sought to determine whether
alteration of FOXM1 levels causes a feedback control on
AMPK activity. To this end, we treated C33A cells with the
FOXM1 specific inhibitor thiostrepton to suppress
FOXM1 expression. Upon treatment of thiostrepton
(5 μM), FOXM1 expression was significantly suppressed,
whereas the expression of p-AMPKα (Thr172) was un-
changed (Figure 4C). Similarly, knockdown of endogenous
FOXM1 using shRNAs did not reveal any discernible
change on the expression level of p-AMPKα (Thr172) in
C33A cells (Figure 4D). Taken together, p-AMPKα activity
per se is not altered by FOXM1 suppression induced by
thiostrepton treatment or shRNA knockdown, implyingcell growth inhibition in cervical cancer cells. (A) XTT cell
th ectopic expression of FOXM1c (OE) were significantly increased as
c expression of FOXM1c showed a less inhibitory effect on cell growth
0 mM). (B) Western blot analysis showed that the level of FOXM1
eated with metformin (25 mM) for 24 hrs. (C) The level of p-AMPKα
ibitor, thiostrepton (5 μM). (D) Depletion of the endogenous FOXM1 by
h1 and sh2 represent two independent pTER–FOXM1 transfections,
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feedback loop. Our analysis strongly supports that
increased AMPK activity down-regulates FOXM1 through
the AKT/FOXO3a/FOXM1 signaling cascade (Figure 5).
Discussion
Recent studies have suggested that targeting cancer cell
metabolism is an alternative therapeutic approach in
cancer treatment. AMPK is a pivotal energy sensor
governing normal and cancer cell metabolism. Our
previous research has shown that pharmaceutical AMPK
activators are able to repress cervical cancer cell growth
through targeting DVL3 in the Wnt/β-catenin signaling
pathway [12]. In this study, we report another molecular
mechanism by which AMPK can retard cervical cancer cell
growth: inhibition of FOXM1 function via AMPK/AKT/
FOXO3a signaling. We demonstrated that AMPK activated
by either micro-environmental stresses or pharmaceutical
AMPK activators could reduce FOXM1 expression through
blocking the AKT/FOXO3a signaling pathway, that in turn
impaired cervical cancer cell growth.
The Forkhead box transcription factor FOXM1 regulates
a number of key cell cycle regulators that control the G1 to
S and the G2 to M transitions [21-26]. Accumulating
evidences have shown that the upregulation of FOXM1 is
often involved in the development of various human
cancers [27-32]. We previously reported that there is a
progressive increase in FOXM1 level in the progression of
human cervical cancer [18]. The inhibition of FOXM1
by genetic or pharmaceutical approach significantlyFigure 5 A schematic diagram to illustrate AMPK/AKT/FOXO3a/FOXM
AMPK down-regulates FOXM1 expression.impairs tumor growth of this cancer in vitro and
in vivo [18,25,27,33], suggesting that targeting FOXM1 is
an appealing and potential approach for anticancer thera-
peutics. On the other hand, we and others have proved that
activation of AMPK is able to inhibit the growth of various
human cancers including cervical cancer [10,34-36]. The
pharmacological activation of AMPK using AICAR or
metformin has been shown to inhibit cell growth and
induce cell apoptosis of a wide spectrum of cancer cells
through modulation of p53 [37], p27 [38,39], or p21
[18,40], or DVL3 in Wnt/β-catenin signaling in cervical
cancer [12]. Herein, we demonstrated that the activation of
AMPK by various AMPK activators or hypoxia and glucose
deprivation stresses induces a remarkable reduction of
FOXM1 which in turn leads to a remarkable decrease of
cervical cancer cell growth in both HPV positive (Caski,
Hela and SiHa) and HPV negative (C33A) cell lines.
On the other hand, ectopic expression of FOXM1c
could counteract the suppressive effect of activated AMPK.
These findings indicate that FOXM1 is a key oncogenic
factor associated with cervical cancer cell growth, while
activated AMPK inhibits cervical cancer cell growth
through downregulation of endogenous FOXM1.
In fact, we demonstrated that reduction of FOXM1
occurred at both the mRNA but and protein levels in
cervical cancer cells. This is suggestive of a transcriptional
suppression of FOXM1 by its upstream effectors. Previous
studies have reported that FOXM1 is transcriptionally
suppressed by FOXO3a, which is a critical downstream
effector of the PI3K/AKT/FOXO signaling pathway [19,20].1 as the proposed molecular mechanism by which activated
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estrogen receptors α (ERα) activity in breast cancer
cells through an alternative mechanism by which
FOXO3a interacts and downregulates the expression
of FOXM1 [29,41]. These evidences imply that the
reduction of FOXM1 at both the mRNA and protein
levels is due to the presence of FOXO3a in cervical
cancer cells. In fact, our data using siRNA-mediated
FOXO3a knockdown showed that FOXO3a expression is
required for FOXM1 reduction upon activation of AMPK.
How do activated AMPK leads to FOXO3a accumulating
in the nucleus and blocking the transcription of
FOXM1 mRNA? FOXO3a, which belongs to the class
O of Forkhead/winged helix box (FOXO) transcription fac-
tors, is a key tumor suppressor involved in different cellular
processes [42]. FOXO3a is modified by phosphorylation,
acetylation and ubiquitination, which in turn affect its
nuclear/cytoplasm shuttling, transcriptional activity and
stability [43-46]. It is known that the PI3K/AKT signaling is
the main regulatory pathway of FOXO3a [44,47,48].
When PI3K/AKT signaling is activated, FOXO3a is
not only inactivated and phosphorylated at Thr32,
Ser253 and Ser315 residues, but is also exported out from
the nucleus to the cytoplasm where it is ubiquitinated and
subjected to proteasome-dependent degradation [43,48].
Therefore, nuclear FOXO3a functions as transcriptional
regulator, whereas cytoplasmic FOXO3a is considered
inactive [46]. On the other hand, AKT is a signaling
kinase known to be inactivated by activated AMPK
[49,50]. In our study, treatment of either AMPK activator
(metformin) or PI3K/AKT inhibitor (LY294002) showed
significant inhibition of p-AKT and a remarkable reduction
of p-FOXO3a (Ser253), an AKT-specific phosphorylation
site, suggesting that suppression of FOXO3a is reduced.
As a result, FOXO3a will be more nuclear-localized
and activated to inhibit FOXM1 mRNA expression in
cervical cancer cells.
Aforementioned, AMPK activation can commonly
inhibit FOXM1 expression in cervical cancer cells.
However, whether there exists a feedback loop on the
activity of AMPK is still unknown. To test this notion,
cervical cancer cells were treated with the FOXM1
inhibitor thiostrepton to investigate the effect on AMPK
activation. Results showed that treatment of thiostrepton
only reduced expression of FOXM1 but not the activity
of AMPK. In addition, depletion of endogenous FOXM1
using shRNAs gave similar findings as the treatment of
thiostrepton, implying that FOXM1 is acting downstream
of AMPK without any feedback regulation.
Conclusion
In summary, our findings here prove that activation
of AMPK frequently inhibits cervical cancer cells.
More importantly, we demonstrated that activatedAMPK reduces FOXM1 by counteracting the AKT/
FOXO3a/FOXM1 signaling axis. Our findings shed
light on the application of AMPK activators in the
treatment of human cervical cancer.
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